Komori
Nissan Chemical (4021) · PolicyAdvanced

Comprehensive Capabilities through the Integration of Proprietary, Internal and External Technologies

First written in FY2017-Q1. 4 of 9 entries say "Restated". Latest entry: FY2026.

9entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017-Q1 – FY2018AdvancedFY2021 – FY20262016: 120162017: 320172018: 120182019: 020192020: 020202021: 120212022: 120222023: 120232024: 020242025: 020252026: 12026
Same theme, other companies
Creating New Products and Customer Value Through the Fusion of Multiple Core TechnologiesA theme 29 companies write about · 0 as a headwind · 29 as a tailwind

The whole theme swung hardest in 2023: 2 of 16 companies on the "Worse" side.

13 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 29 companies compared. The sentences above are computed from all 29.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「We aim to acquire expertise in information science and microbial control.」

    In addition to the five core technologies, the company has specified the expansion of its technology platform by cultivating information science and microbial control as new technologies, consolidating research personnel, and pursuing data-driven research.
  2. FY2023AdvancedAnnual report

    「In addition to the five core technologies developed to date, namely precision organic synthesis, functional polymer design, fine-particle control, biological evaluation, and optical control, we will cultivate the new technologies of microbial control and information science」

    The company has expanded its technology platform by explicitly stating its intention to add and cultivate microbial control and information science as new technologies alongside its five existing core technologies.
  3. FY2022AdvancedAnnual report

    「We will create new products and businesses and establish a growth trajectory by acquiring new core technologies and integrating and deepening them with our existing core technologies.」

    The company has moved from a policy based on its five existing core technologies to specific measures involving the acquisition of new core technologies, their integration with and further development of existing technologies, and the creation of new products and businesses.
  4. FY2021AdvancedAnnual report

    「Our group is based on the five core technologies developed to date: precision organic synthesis, functional polymer design, fine-particle control, biological evaluation, and optical control」

    The company has expanded its description of its technology platform by adding optical control to the previously identified core technologies, resulting in five core technologies.
  5. FY2018RestatedAnnual report

    「Building on the proprietary technologies we have developed to date, we are incorporating new technologies and working to develop materials that meet the needs of the times.」

    The company continues its policy of developing materials based on proprietary technologies while incorporating new technologies and pursuing external collaboration.
  6. FY2018-Q1RestatedAnnual report

    「We believe that the sources of corporate value are our integrated capabilities, which combine our proprietary technologies in each of our group's businesses with technologies from inside and outside the company to develop products sought by society, together with the corporate culture that provides the foundation for exercising these capabilities.」

    The company continues to describe its proprietary technologies, combination of in-house and external technologies, and corporate culture as sources of corporate value.
  7. FY2017RestatedAnnual report

    「We are pursuing the development of new fields by combining our core technologies: precision organic synthesis, functional polymer design, fine-particle control, and biological evaluation.」

    The company continues to describe the development of new fields through the integration of proprietary technologies as part of its technology platform.
  8. FY2017-Q3RestatedAnnual report

    「We believe that the sources of corporate value are our integrated capabilities, which combine our proprietary technologies in each of our group's businesses with technologies from inside and outside the company to develop products sought by society, together with the corporate culture that provides the foundation for exercising these capabilities.」

    The company continues to describe its proprietary technologies, combination of in-house and external technologies, and corporate culture as sources of corporate value.
  9. FY2017-Q1First statedAnnual report

    「We believe that the sources of corporate value are our integrated capabilities, which combine our proprietary technologies in each of our group's businesses with technologies from inside and outside the company to develop products sought by society, together with the corporate culture that provides the foundation for exercising these capabilities.」

    The company describes its proprietary technologies, combination of in-house and external technologies, and corporate culture as sources of corporate value.
Moved together

"Operating Profit, Ordinary Profit and Profit Attributable to Owners of the Parent Reach New Record Highs" moved the same way as this thread, in the same document, in 4 of its 9 moves.

444444★123456
  1. ★This thread
  2. 1Operating Profit, Ordinary Profit and Profit Attributable to Owners of the Parent Reach New Record Highs4×
  3. 2Continuing Research and Development Activities4×
  4. 3Global rollout of the fluralaner product Bravecto and strengthening of the production system4×
  5. 4Domestic and Overseas Registration and Launch of Agrochemical Products and Expansion of Sales Channels4×
  6. 5Investment in manufacturing and research facilities and development of facilities for new products4×
  7. 6Advancing Clinical Development of the Drug Discovery Pipeline and External Partnerships4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Nissan Chemical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Comprehensive Capabilities through the Integration of Proprietary, Internal and External Technologies | Nissan Chemical Corporation (4021) | Komori